1. SAT0222 BIIB059, a monoclonal antibody targeting BDCA2, shows evidence of biological activity and early clinical proof of concept in subjects with active cutaneous le. (15th June 2017) Authors: Furie, R; Werth, VP; Merola, JF; Reynolds, TL; Stevenson, L; Wang, W; Smirnakis, K; Barbey, C; Musselli, C; Werneburg, B; Rabah, D; Franchimont, N Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 857 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗